Nara
← Intervention Library

Experimental and investigational

Rapamycin

The most scientifically important experimental canine longevity intervention, and still a medication-level decision.

Nara’s current positionClinical-trial only
Evidence briefing

Strongest directness: Canine function. Last reviewed 2026-08-12.

Nara’s evidence view

Clinical-trial context only

Insufficient or conflictingCanine functional outcomesLow confidence

The claim we’re evaluating

Intermittent low-dose rapamycin has sufficient canine geroscience evidence to justify continued investigation, but available trials do not demonstrate improved canine healthspan or lifespan and provide inconsistent evidence for cardiac benefit across regimens.

Nara’s interpretation

Rapamycin has unusually strong geroscience plausibility and more direct canine evidence than most experimental longevity drugs, but the canine results are not equivalent to a longevity result. A short trial reported favorable cardiac changes whereas a longer lower-dose trial did not reproduce a significant echocardiographic benefit. Until TRIAD or comparable trials report healthspan and survival outcomes, Nara should not say that rapamycin makes dogs live longer.

This is an umbrella assessment. The evidence differs materially depending on the outcome and the specific form of the intervention, so Nara evaluates those narrower claims separately.

Personalized

What this means for your dog.

Loading your dog’s context…

Evidence briefing

What Nara knows now.

A bounded position while the full claim-level dossier is still being completed.

What is known

A 2017 randomized trial in 24 healthy middle-aged companion dogs reported favorable changes in several echocardiographic measures after 10 weeks of intermittent rapamycin at 0.05 or 0.1 mg/kg three times weekly, with no overt clinical toxicity. A later masked randomized trial in 17 healthy dogs used 0.025 mg/kg three times weekly for six months and found no statistically significant echocardiographic difference at six or twelve months. A severe reversible hypertriglyceridemia case occurred in a treated dog. TRIAD is designed around aging, healthspan, and lifespan endpoints; its published protocol shows those questions are being tested, not answered.

What is not known

The two completed healthy-dog randomized trials were very small and used materially different dose, cumulative exposure, and treatment duration. The favorable cardiac signal in the first trial was not reproduced at statistical significance in the longer lower-dose study. Echocardiographic changes are not equivalent to lower disease burden, improved healthspan, or longer lifespan. Available safety datasets are too small to characterize uncommon adverse events or long-term risk reliably.

Current position

Rapamycin has unusually strong geroscience plausibility and more direct canine evidence than most experimental longevity drugs, but the canine results are not equivalent to a longevity result. A short trial reported favorable cardiac changes whereas a longer lower-dose trial did not reproduce a significant echocardiographic benefit. Until TRIAD or comparable trials report healthspan and survival outcomes, Nara should not say that rapamycin makes dogs live longer.

A 2017 randomized trial in 24 healthy middle-aged companion dogs reported favorable changes in several echocardiographic measures after 10 weeks of intermittent rapamycin at 0.05 or 0.1 mg/kg three times weekly, with no overt clinical toxicity. A later masked randomized trial in 17 healthy dogs used 0.025 mg/kg three times weekly for six months and found no statistically significant echocardiographic difference at six or twelve months. A severe reversible hypertriglyceridemia case occurred in a treated dog. TRIAD is designed around aging, healthspan, and lifespan endpoints; its published protocol shows those questions are being tested, not answered.